Moran Sean F. 4
4 · Corbus Pharmaceuticals Holdings, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
Corbus (CRBP) CFO Sean Moran Sells 4,701 Shares
What Happened
Sean F. Moran, Chief Financial Officer of Corbus Pharmaceuticals Holdings, sold 4,701 shares in an open-market transaction on February 13, 2026. The weighted-average sale price was $7.78, producing total proceeds of approximately $36,588. The filing lists this as a sale (S) and notes the shares were sold to satisfy tax-withholding obligations tied to RSU vesting — not as a discretionary trade.
Key Details
- Transaction date: 2026-02-13; weighted-average price: $7.78; total value: ~$36,588.
- Price range: shares were sold in multiple trades at prices between $7.58 and $7.96. The filer can provide a per-price breakdown on request.
- Reason: Sale effected under a Rule 10b5-1 trading plan adopted March 14, 2025, and mandated by the issuer’s "sell-to-cover" tax-withholding election (i.e., routine tax withholding).
- Shares owned after transaction: the filing notes that the reported ownership figure includes 68,795 unvested RSUs subject to previously reported vesting schedules. (The total post-sale beneficial ownership figure was not provided in the data supplied here.)
- Filing timing: Form 4 was filed on 2026-02-18 for a 2026-02-13 trade. Given Form 4 is normally due within two business days, this appears to have been filed late by one business day (Feb 16, 2026 was a federal holiday).
Context
This was a routine, non-discretionary "sell to cover" tied to RSU vesting and executed under a pre-established 10b5-1 plan. Such transactions are typically done to satisfy tax obligations and should not be read as an independent signal of the insider’s view on the company’s stock.
Insider Transaction Report
- Sale
Common Stock, par value $0.0001 per share
[F1][F2][F3]2026-02-13$7.78/sh−4,701$36,588→ 96,694 total
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025 and the sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.58 to $7.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This amount includes 68,795 unvested RSUs subject to each grant's vesting schedule as previously reported.